Su evaluación y manejo clínico | 26 NOV 20

Crisis suprarrenales en pacientes de edad avanzada

Son manifestaciones graves de la insuficiencia suprarrenal que requieren la hospitalización y conllevan un riesgo de eventos cardiovasculares, lesión renal aguda y muerte.
Autor/a: Ruth L Rushworth, David J Torpy, Henrik Falhammar Lancet Diabetes Endocrinol 2020; 8: 62839
INDICE:  1. Texto principal | 2. Referencias bibliográficas
Referencias bibliográficas

1 Hahner S, Spinnler C, Fassnacht M, et al. High incidence of adrenal crisis in educated patients with chronic adrenal insufficiency: a prospective study. J Clin Endocrinol Metab 2015; 100: 407–16.

2 Erichsen MM, Lovas K, Fougner KJ, et al. Normal overall mortality rate in Addison’s disease, but young patients are at risk of premature death. Eur J Endocrinol 2009; 160: 233–37.

3 Falhammar H, Frisén L, Norrby C, et al. Increased mortality in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 2014; 99: e2715–21.

4 Burman P, Mattsson AF, Johannsson G, et al. Deaths among adult patients with hypopituitarism: hypocortisolism during acute stress, and de novo malignant brain tumors contribute to an increased mortality. J Clin Endocrinol Metab 2013; 98: 1466–75.

5 Bergthorsdottir R, Leonsson-Zachrisson M, Odén A, Johannsson G. Premature mortality in patients with Addison’s disease: a population-based study. J Clin Endocrinol Metab 2006; 91: 4849–53.

6 Tomlinson JW, Holden N, Hills RK, et al. Association between premature mortality and hypopituitarism. Lancet 2001; 357: 425–31.

7 Bensing S, Brandt L, Tabaroj F, et al. Increased death risk and altered cancer incidence pattern in patients with isolated or combined autoimmune primary adrenocortical insufficiency. Clin Endocrinol (Oxf) 2008; 69: 697–704.

8 Ebrahimi F, Widmer A, Wagner U, et al. Association of adrenal insufficiency with patient-oriented health-care outcomes in adult medical inpatients. Eur J Endocrinol 2019; 181: 701–09.

9 Rushworth RL, Torpy DJ. A descriptive study of adrenal crises in adults with adrenal insufficiency: increased risk with age and in those with bacterial infections. BMC Endocr Disord 2014; 14: 79.

10 Chen YC, Chen YC, Chou LF, Chen TJ, Hwang SJ. Adrenal insufficiency in the elderly: a nationwide study of hospitalizations in Taiwan. Tohoku J Exp Med 2010; 221: 281–85.

11 Allolio B. Extensive expertise in endocrinology. Adrenal crisis. Eur J Endocrinol 2015; 172: R115–24.

12 Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2016; 101: 364–89.

13 Rushworth RL, Torpy DJ, Falhammar H. Adrenal crisis. N Engl J Med 2019; 381: 852–61.

14 Rushworth RL, Torpy DJ. Adrenal insufficiency in Australia: is it possible that the use of lower dose, short-acting glucocorticoids has increased the risk of adrenal crises? Horm Metab Res 2015; 47: 427–32.

15 Regal M, Páramo C, Sierra SM, Garcia-Mayor RV. Prevalence and incidence of hypopituitarism in an adult Caucasian population in northwestern Spain. Clin Endocrinol (Oxf) 2001; 55: 735–40.

6 Rushworth RL, Torpy DJ, Falhammar H. Adrenal crises: perspectives and research directions. Endocrine 2017; 55: 336–45.

17 Feelders RA, Newell-Price J, Pivonello R, Nieman LK, Hofland LJ, Lacroix A. Advances in the medical treatment of Cushing’s syndrome. Lancet Diabetes Endocrinol 2019; 7: 300–12.

18 Donegan D, Bancos I. Opioid-induced adrenal insufficiency. Mayo Clin Proc 2018; 93: 937–44.

19 Rushworth RL, Torpy DJ, Falhammar H. Adrenal Crisis. Reply. N Engl J Med 2019; 381: 2182–83. 20 Vuong C, Van Uum SH, O’Dell LE, Lutfy K, Friedman TC. The effects of opioids and opioid analogs on animal and human endocrine systems. Endocr Rev 2010; 31: 98–132. 21 Lamprecht A, Sorbello J, Jang C, Torpy DJ, Inder WJ. Secondary adrenal insufficiency and pituitary dysfunction in oral/transdermal opioid users with non-cancer pain. Eur J Endocrinol 2018; 179: 353–62.

22 Puar TH, Stikkelbroeck NM, Smans LC, Zelissen PM, Hermus AR. Adrenal crisis: still a deadly event in the 21st century. Am J Med 2016; 129: 339.e1–9. 23 Reisch N, Willige M, Kohn D, et al. Frequency and causes of adrenal crises over lifetime in patients with 21-hydroxylase deficiency. Eur J Endocrinol 2012; 167: 35–42.

24 Smans LC, Van der Valk ES, Hermus AR, Zelissen PM. Incidence of adrenal crisis in patients with adrenal insufficiency. Clin Endocrinol (Oxf) 2016; 84: 17–22.

25 Meyer G, Badenhoop K, Linder R. Addison’s disease with polyglandular autoimmunity carries a more than 2·5-fold risk for adrenal crises: German Health insurance data 2010–2013. Clin Endocrinol (Oxf) 2016; 85: 347–53.

26 White K, Arlt W. Adrenal crisis in treated Addison’s disease: a predictable but under-managed event. Eur J Endocrinol 2010; 162: 115–20.

27 Rushworth RL, Torpy DJ. Modern hydrocortisone replacement regimens in adrenal insufficiency patients and the risk of adrenal crisis. Horm Metab Res 2015; 47: 637–42.

28 El-Maouche D, Hargreaves CJ, Sinaii N, Mallappa A, Veeraraghavan P, Merke DP. Longitudinal assessment of illnesses, stress dosing, and illness sequelae in patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2018; 103: 2336–45.

29 Iwasaku M, Shinzawa M, Tanaka S, Kimachi K, Kawakami K. Clinical characteristics of adrenal crisis in adult population with and without predisposing chronic adrenal insufficiency: a retrospective cohort study. BMC Endocr Disord 2017; 17: 58.

30 Hahner S, Loeffler M, Bleicken B, et al. Epidemiology of adrenal crisis in chronic adrenal insufficiency: the need for new prevention strategies. Eur J Endocrinol 2010; 162: 597–602.

31 Rushworth RL, Chrisp GL, Torpy DJ. Glucocorticoid-induced adrenal insufficiency: a study of the incidence in hospital patients and a review of peri-operative management. Endocr Pract 2018; 24: 437–45.

32 Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol 2011; 335: 2–13.

33 Annane D, Bellissant E, Sebille V, et al. Impaired pressor sensitivity to noradrenaline in septic shock patients with and without impaired adrenal function reserve. Br J Clin Pharmacol 1998; 46: 589–97.

34 Macfarlane DP, Forbes S, Walker BR. Glucocorticoids and fatty acid metabolism in humans: fuelling fat redistribution in the metabolic syndrome. J Endocrinol 2008; 197: 189–204.

}35 Ramamoorthy S, Cidlowski JA. Corticosteroids: mechanisms of action in health and disease. Rheum Dis Clin North Am 2016; 42: 15–31.vii.

36 Falhammar H, Thorén M. Clinical outcomes in the management of congenital adrenal hyperplasia. Endocrine 2012; 41: 355–73.

37 Hahner S. Acute adrenal crisis and mortality in adrenal insufficiency: Still a concern in 2018! Ann Endocrinol (Paris) 2018; 79: 164–66.

38 Keh D, Boehnke T, Weber-Cartens S, et al. Immunologic and hemodynamic effects of “low-dose” hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study. Am J Respir Crit Care Med 2003; 167: 512–20.

39 Werumeus Buning J, Touw DJ, Brummelman P, et al. Pharmacokinetics of oral hydrocortisone—Results and implications from a randomized controlled trial. Metabolism 2017; 71: 7–16.

40 Werumeus Buning J, Brummelman P, Koerts J, et al. Hydrocortisone dose influences pain, depressive symptoms and perceived health in adrenal insufficiency: a randomized controlled trial. Neuroendocrinology 2016; 103: 771–78.

41 Yiallouris A, Tsioutis C, Agapidaki E, et al. Adrenal aging and its implications on stress responsiveness in humans. Front Endocrinol (Lausanne) 2019; 10: 54.}

42 Hahner S, Burger-Stritt S, Allolio B. Subcutaneous hydrocortisone administration for emergency use in adrenal insufficiency. Eur J Endocrinol 2013; 169: 147–54.

43 Goubar T, Torpy DJ, McGrath S, Rushworth RL. Prehospital management of acute Addison disease: audit of patients attending a referral hospital in a regional area. J Endocr Soc 2019; 3: 2194–203.

44 Rushworth RL, Chrisp GL, Torpy DJ. The use of medical identification jewellery in adults with adrenal insufficiency in Australia. Clin Endocrinol (Oxf) 2019; 91: 41–47.

45 Speiser PW, Arlt W, Auchus RJ, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2018; 103: 4043–88.

46 Gidlöf S, Falhammar H, Thilén A, et al. One hundred years of congenital adrenal hyperplasia in Sweden: a retrospective, population-based cohort study. Lancet Diabetes Endocrinol 2013; 1: 35–42.

47 Løvås K, Husebye ES. High prevalence and increasing incidence of Addison’s disease in western Norway. Clin Endocrinol (Oxf) 2002; 56: 787–91. 48 Laugesen K, Jorgensen JOL, Petersen I, Sorensen HT. Fifteen-year nationwide trends in systemic glucocorticoid drug use in Denmark. Eur J Endocrinol 2019; 181: 267–73.

49 Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol 2018; 4: 173–82.

50 Lu J, Li L, Lan Y, Liang Y, Meng H. Immune checkpoint inhibitor-associated pituitary–adrenal dysfunction: a systematic review and meta-analysis. Cancer Med 2019; 8: 7503–15.

51 Tallis PH, Rushworth RL, Torpy DJ, Falhammar H. Adrenal insufficiency due to bilateral adrenal metastases— a systematic review and meta-analysis. Heliyon 2019; 5: e01783.

52 Papierska L, Rabijewski M. Delay in diagnosis of adrenal insufficiency is a frequent cause of adrenal crisis. Int J Endocrinol 2013; 2013: 482370.

53 Yo WS, Toh LM, Brown SJ, Howe WD, Henley DE, Lim EM. How good is a morning cortisol in predicting an adequate response to intramuscular synacthen stimulation? Clin Endocrinol (Oxf) 2014; 81: 19–24.

54 Brown S, Hadlow N, Badshah I, Henley D. A time-adjusted cortisol cut-off can reduce referral rate for Synacthen stimulation test whilst maintaining diagnostic performance. Clin Endocrinol (Oxf) 2017; 87: 418–24.

55 El-Farhan N, Pickett A, Ducroq D, et al. Method-specific serum cortisol responses to the adrenocorticotrophin test: comparison of gas chromatography–mass spectrometry and five automated immunoassays. Clin Endocrinol (Oxf) 2013; 78: 673–80.

56 Venkatesh B, Mortimer RH, Couchman B, Hall J. Evaluation of random plasma cortisol and the low dose corticotropin test as indicators of adrenal secretory capacity in critically ill patients: a prospective study. Anaesth Intensive Care 2005; 33: 201–09.

57 Crowther S, Rushworth RL, Rankin W, Falhammar H, Phillips LK, Torpy DJ. Trends in surgery, hospital admissions and imaging for pituitary adenomas in Australia. Endocrine 2018; 59: 373–82. 58 Chen YC, Lin YH, Chen SH, et al. Epidemiology of adrenal insufficiency: a nationwide study of hospitalizations in Taiwan from 1996 to 2008. J Chin Med Assoc 2013; 76: 140–45.

59 Ono Y, Ono S, Yasunaga H, Matsui H, Fushimi K, Tanaka Y. Clinical features and practice patterns of treatment for adrenal crisis: a nationwide cross-sectional study in Japan. Eur J Endocrinol 2017; 176: 329–37.

 

Comentarios

Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

CONTENIDOS RELACIONADOS
AAIP RNBD
Términos y condiciones de uso | Todos los derechos reservados | Copyright 1997-2023